| INTRODUCTION
Medical management is the mainstay of treatment for Crohn's disease (CD). Available therapeutic options suppress the immune response to control gut inflammation, with an aim of alleviating patient symptoms, improving quality of life, and achieving endoscopic and histologic healing. 1 The treatment armamentarium for CD currently includes corticosteroids, aminosalicylates, immunosuppressants, tumour necrosis factor (TNF) antagonists, anti-adhesion agents and an inhibitor of the interleukin 12/23 pathway. 2 Traditionally, management of CD has been based on a "step-up" model of care, beginning with less effective but potentially safer therapies and sequentially intensifying treatment to achieve remission. 3 However, as more effective therapies have become available, treatment paradigms have evolved to favour the earlier introduction of highly effective therapies with the intent of modifying the disease course and preventing longer term bowel damage. 4 Although treatment algorithms have evolved, aminosalicylates remain the most commonly prescribed drug class in CD and are used for induction or maintenance of remission, or for prevention of postoperative recurrence. 5 However, in contrast to ulcerative colitis, there is uncertainty regarding their effectiveness in CD. Meta-analyses of randomised controlled trials (RCTS) have found no evidence that oral mesalazine preparations are superior to placebo for either induction or maintenance of remission and sulfasalazine has only modest benefit as an induction agent. 5, 6 Accordingly, European and American consensus guidelines either recommend against or make no recommendation on the use of aminosalicylates in CD. 3, 7, 8 Despite these findings, several population-based cohort studies from North America and Europe have demonstrated that approximately 40%-60% of CD patients receive aminosalicylates. 9, 10 A retrospective analysis of insurance claims from 13 005 CD patients performed by Rubin et al demonstrated that 47% were prescribed aminosalicylates as their index treatment. 11 In the Manitoba Inflammatory Bowel Disease (IBD) Epidemiology database, 62% of more than 4000 CD patients had ever used aminosalicylates. 9 Among the 1420 CD patients treated between 2006 and 2012 in the Swiss IBD cohort, 59% of patients received an aminosalicylate during their disease course. 10 Finally, a retrospective analysis of prescribing practices for senior CD patients in the United States, United Kingdom,
Denmark and Canada between 2004 and 2009 revealed that
although there was some decrease in use over time, 60%-70% of CD patients were prescribed aminosalicylates. 12 The high use of aminosalicylates reported in the aforementioned studies is surprising given their uncertain effectiveness in CD, indicating a marked disparity between the evidence base and clinical practice.
To provide a more global perspective, we conducted a meta-analysis of the placebo arms of all placebo-controlled RCTs in CD to determine the proportion of CD patients taking concomitant oral aminosalicylates at trial entry. We evaluated how aminosalicylate usage rates have evolved over time, explored factors predictive of aminosalicylate use, and estimated annual direct costs associated with treatment in CD. 
| MATERIALS AND METHODS

| Study eligibility criteria
Eligible studies were randomised, placebo-controlled induction and/ or maintenance trials in adults with CD that evaluated a corticosteroid, immunosuppressant, or biological agent; used the Crohn's Disease Activity Index (CDAI) 13 or Harvey Bradshaw Index (HBI) 14 as enrolment criteria; and reported the number of patients at trial entry who were co-prescribed an oral aminosalicylate. We restricted the inclusion to studies utilising the CDAI or HBI to ensure this review is relevant to contemporary practice. Although other activity indices in CD have been described, they are primarily of historical relevance. Trials of fistulising or post-operative prevention of CD were excluded. Studies where all patients were on concomitant aminosalicylates or trials where concomitant aminosalicylate use was contraindicated were excluded from meta-analysis.
| Outcome assessment and data extraction
Articles were independently assessed by 2 investigators (CEP, TMN) and disagreement was resolved by consensus and discussion with a third reviewer (VJ). All data were extracted independently and in duplicate. The primary outcome extracted was the proportion of patients taking aminosalicylates at baseline in the placebo arm. Additional features extracted related to: (a) trial design characteristics (induction/maintenance design, year of publication, number of participants in placebo arm, study duration); (b) drug class (corticosteroid, immunosuppressant, biologic); and (c) disease-related characteristics (disease duration, severity and distribution).
We evaluated only the placebo group to estimate concomitant aminosalicylate use. Data for this analysis were derived from our previous work evaluating placebo rates in CD, where aminosalicylate use in the active comparator arm was not collected. 15 However, the process of randomisation distributes covariates equally among all treatment assignments and thus, our point estimates of the proportion of patients on aminosalicylates in the placebo group should not differ systematically from the proportion among patients randomised to active CD patients treated with aminosalicylates from the meta-analysis.
Specifically, we estimated costs for commonly prescribed formulations of sulfasalazine (PMS-sulfasalazine, salazopyrin) and mesalazine (novo-5ASA, Mezavant/Lialda, Asacol, Mesasal, Pentasa, Salofalk).
ODB price per unit, typical daily doses, daily costs and annual costs of treatment were estimated. Similar prices are paid by other provincial pharmacy formularies throughout Canada. All costs are presented in 2016 Canadian dollars (CAD).
| RESULTS
| Search results and included studies
Forty-two induction [16] [17] [18] [19] [20] [21] [22] [23] [24] and 10 maintenance trials 16, 25, 41, 43, 53, [60] [61] [62] [63] [64] were included (Table S1 ). The flow diagram for inclusion of trials identified by the literature search is illustrated in Figure S1 and trial characteristics are summarised in Table 1 
| Aminosalicylate use in induction and maintenance trials
For induction trials, the pooled proportion of patients in the placebo arms using aminosalicylates was 44% [95% CI: 39%-49%] ( Table 2 ; Figure 1 ), with a substantial degree of heterogeneity observed between studies (I 2 = 86.0%, P <0.0001).
In univariable meta-regression of induction trials ( with a considerable degree of heterogeneity observed between studies (I 2 = 91.8%, P < 0.0001). In univariable meta-regression ( Figure 3A) . In more recent trials published from 2012 onwards, 38% [95% CI: 27%-48%] of enrolled patients were on concomitant aminosalicylates (Figure S2 ). In contrast, the proportion of patients prescribed concomitant aminosalicylates in maintenance trials has remained relatively stable at approximately 50% ( Figure 3B ).
| Estimated direct drug treatment costs for aminosalicylates
Based on drug prices in Ontario, Canada in 2016, the average annual cost of aminosalicylate use per patient ranges from $400 to $870 CAD for sulfasalazine and from $700 to $1230 CAD for mesalazine, depending on the formulation, brand and dose (Table 6 ). Based on a conservative estimate of 35% aminosalicylate use rate in CD and priced at the lowest cost mesalazine preparation, the annual estimated direct drug-related cost is $2.5 million per 10 000 CD patients resulting in a total cost of at least $32 million each year for the CD population in Canada (~130 000 patients). 65 67 Not surprisingly, aminosalicylates are often used as first line therapy in step-up models of CD care, with up to 50% of CD patients prescribed aminosalicylates within the first year of diagnosis. 68 Although this is supported in our multivariable analysis where disease duration >7 years was inversely associated with aminosalicylate use, the observation from our study that over one-third of patients entering modern day RCTs of moderate-to-severe CD are co-prescribed aminosalicylates contradicts the common perception that this is a treatment reserved only for patients with milder disease. 1.14-3.14]) for induction of remission in CD, but only when using
| DISCUSSION
Bayesian network meta-analytical methods. 70 Other network meta- speaker's fees from Takeda, Janssen, Shire, Ferring.
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